£1.5 million placing supporting growth of ACCRUFeR

London, UK, September 15, 2025: Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that the completion of a placing (the "Placing") to raise gross proceeds of £1.5 million through the issue of 20,000,000 new ordinary shares ("New Ordinary Shares") in the capital of the Company at a price of 7.5 pence per share (the "Issue Price"). This Placing resulted from unsolicited institutional investor demand.

The Issue Price represents a premium of approximately 5% to the 30-day VWAP (Volume Weighted Average Price) of 7.13 pence per existing Ordinary Share to 12 September 2025, being the last trading day prior to the publication this announcement. The Placing Shares, in aggregate, represent approximately 1.9% of the existing issued ordinary share capital of the Company.

Application has been made to London Stock Exchange plc for the Placing Shares to be admitted to trading on AIM ("Admission"). Admission is expected to take place on 19 September 2025. The Placing Shares will be fully paid and will rank pari passu in all respects with the existing Ordinary Shares.

Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 1,061,690,484 with equal voting rights. No shares are held in treasury.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company's share capital pursuant to (i) the Company's Articles, (ii) the Financial Conduct Authority's Disclosure Guidance and Transparency Rules and/or (iii) the AIM Rules for Companies issued by the London Stock Exchange plc as amended from time to time.

Santosh Shanbhag, CFO at Shield, commented: "We are pleased with the continued momentum of ACCRUFeR® growth in the US which has now become the #1 branded prescription oral iron in the market today. This placing is in the best interests of the Company by broadening its institutional shareholder base and whilst we remain confident in turning cash flow positive by the end of 2025 it also further strengthens the Company's working capital position allowing the Board and management to focus completely on accelerating sales of ACCRUFeR®"

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).

About CMC Markets UK Plc

CMC was established in 1989 and is a FTSE250 listed company. CMC is the second largest domestic stockbroker in Australia, and the group has offices in fourteen countries, with major hubs based in the UK, Germany, Dubai, Singapore, Australia & Canada servicing clients from all around the globe. CMC employs more than fourteen hundred staff and has around one million clients globally.